Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBITDA (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EBITDA for 16 consecutive years, with -$49.6 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA fell 1552.02% year-over-year to -$49.6 million; the TTM value through Mar 2026 reached -$8.2 million, down 107.41%, while the annual FY2025 figure was $44.8 million, 67.29% down from the prior year.
  • EBITDA hit -$49.6 million in Q1 2026 for Corcept Therapeutics, down from $4.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $46.6 million in Q3 2024 and bottomed at -$49.6 million in Q1 2026.
  • Average EBITDA over 5 years is $20.4 million, with a median of $26.7 million recorded in 2025.
  • Year-over-year, EBITDA soared 98.61% in 2024 and then tumbled 1552.02% in 2026.
  • Corcept Therapeutics' EBITDA stood at $22.5 million in 2022, then soared by 40.76% to $31.7 million in 2023, then dropped by 20.23% to $25.3 million in 2024, then crashed by 82.24% to $4.5 million in 2025, then crashed by 1205.44% to -$49.6 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$49.6 million, $4.5 million, and $10.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.